全文获取类型
收费全文 | 97700篇 |
免费 | 9873篇 |
国内免费 | 2933篇 |
专业分类
耳鼻咽喉 | 443篇 |
儿科学 | 1421篇 |
妇产科学 | 850篇 |
基础医学 | 6644篇 |
口腔科学 | 1510篇 |
临床医学 | 10055篇 |
内科学 | 13578篇 |
皮肤病学 | 2610篇 |
神经病学 | 4475篇 |
特种医学 | 1362篇 |
外国民族医学 | 18篇 |
外科学 | 4739篇 |
综合类 | 11335篇 |
现状与发展 | 9篇 |
一般理论 | 9篇 |
预防医学 | 8128篇 |
眼科学 | 1988篇 |
药学 | 31271篇 |
47篇 | |
中国医学 | 3704篇 |
肿瘤学 | 6310篇 |
出版年
2024年 | 257篇 |
2023年 | 1770篇 |
2022年 | 2879篇 |
2021年 | 4142篇 |
2020年 | 4007篇 |
2019年 | 3924篇 |
2018年 | 3816篇 |
2017年 | 4071篇 |
2016年 | 3902篇 |
2015年 | 3901篇 |
2014年 | 6356篇 |
2013年 | 9669篇 |
2012年 | 6015篇 |
2011年 | 6218篇 |
2010年 | 4981篇 |
2009年 | 4539篇 |
2008年 | 4326篇 |
2007年 | 4348篇 |
2006年 | 3862篇 |
2005年 | 3453篇 |
2004年 | 2976篇 |
2003年 | 2670篇 |
2002年 | 2164篇 |
2001年 | 1978篇 |
2000年 | 1606篇 |
1999年 | 1440篇 |
1998年 | 1256篇 |
1997年 | 1163篇 |
1996年 | 1006篇 |
1995年 | 897篇 |
1994年 | 797篇 |
1993年 | 708篇 |
1992年 | 752篇 |
1991年 | 647篇 |
1990年 | 514篇 |
1989年 | 435篇 |
1988年 | 427篇 |
1987年 | 387篇 |
1986年 | 308篇 |
1985年 | 396篇 |
1984年 | 302篇 |
1983年 | 225篇 |
1982年 | 214篇 |
1981年 | 172篇 |
1980年 | 131篇 |
1979年 | 102篇 |
1978年 | 104篇 |
1977年 | 73篇 |
1976年 | 76篇 |
1975年 | 67篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
51.
欧洲药品局(EMA)于2018年11月发布了"人用药品辅料右旋糖酐的包装说明书资料",该文件引用大量文献全面评价了右旋糖酐的安全性,特别指出含有右旋糖酐辅料的注射和吸入制剂的疫苗与药品,应在说明书中描述有关其过敏反应信息的新要求。介绍该文件的主要内容,期望对我国这类药品说明书的撰写和监管有所帮助。 相似文献
52.
53.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
54.
55.
56.
57.
58.
血吸虫病是一种严重危害人类健康、影响社会经济发展的重大传染病,为全球公共卫生负担和危害最严重的被忽视的热带病之一。吡喹酮是20世纪70年代研制出的一种高效、低毒、价廉的广谱抗蠕虫口服药,为世界卫生组织(WHO)推荐的抗血吸虫的首选药物。吡喹酮在血吸虫病流行区现场大规模反复使用已超过40年,血吸虫是否会对吡喹酮产生抗药性引起国际社会极大担忧,为学术界关注的热点科学问题。针对血吸虫病防治中这一重大需求,自1996年起, 在国家科技支撑计划、国家自然科学基金、江苏省自然科学基金等项目基金资助下,我们在血吸虫病流行区现场和实验室,对血吸虫在吡喹酮药物的压力是否会产生抗药性、抗性虫株的生物学特性、抗性的检测、吡喹酮抗性的交叉抗药性及抗药性的预防和控制等科学问题进行较为系统的研究,本文就其研究及其意义作一概述。 相似文献
59.
Stress Testing Versus CT Angiography in Patients With Diabetes and Suspected Coronary Artery Disease
Abhinav Sharma Adrian Coles Nishant K. Sekaran Neha J. Pagidipati Michael T. Lu Daniel B. Mark Kerry L. Lee Hussein R. Al-Khalidi Udo Hoffmann Pamela S. Douglas 《Journal of the American College of Cardiology》2019,73(8):893-902
Background
The optimal noninvasive test (NIT) for patients with diabetes and stable symptoms of coronary artery disease (CAD) is unknown.Objectives
The purpose of this study was to assess whether a diagnostic strategy based on coronary computed tomographic angiography (CTA) is superior to functional stress testing in reducing adverse cardiovascular (CV) outcomes (CV death or myocardial infarction [MI]) among symptomatic patients with diabetes.Methods
PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) was a randomized trial evaluating an initial strategy of CTA versus functional testing in stable outpatients with symptoms suggestive of CAD. The study compared CV outcomes in patients with diabetes (n = 1,908 [21%]) and without diabetes (n = 7,058 [79%]) based on their randomization to CTA or functional testing.Results
Patients with diabetes (vs. without) were similar in age (median 61 years vs. 60 years) and sex (female 54% vs. 52%) but had a greater burden of CV comorbidities. Patients with diabetes who underwent CTA had a lower risk of CV death/MI compared with functional stress testing (CTA: 1.1% [10 of 936] vs. stress testing: 2.6% [25 of 972]; adjusted hazard ratio: 0.38; 95% confidence interval: 0.18 to 0.79; p = 0.01). There was no significant difference in nondiabetic patients (CTA: 1.4% [50 of 3,564] vs. stress testing: 1.3% [45 of 3,494]; adjusted hazard ratio: 1.03; 95% confidence interval: 0.69 to 1.54; p = 0.887; interaction term for diabetes p value = 0.02).Conclusions
In diabetic patients presenting with stable chest pain, a CTA strategy resulted in fewer adverse CV outcomes than a functional testing strategy. CTA may be considered as the initial diagnostic strategy in this subgroup. (PROspective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550) 相似文献60.